Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,146 Related to Vascepa(R) and FDA Approved MARINE Indication
February 07, 2013 07:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Notification of Additional U.S. Patent Allowance for U.S. Application 13/272,520 Based on ANCHOR Clinical Trial Results
February 01, 2013 07:30 ET
|
Amarin Corporation plc
Patent Application Related to High (≥200 mg/dL to <500 mg/dL) Triglyceride Patient Population With Mixed Dyslipidemia
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 1, 2013 (GLOBE NEWSWIRE)...
Amarin Announces Notification of Two Additional Patent Allowances for U.S. Applications (13/458,496 and 13/349,157) Related to Vascepa(R) and FDA Approved MARINE Indication
January 31, 2013 07:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Market Introduction of Vascepa(R) (icosapent ethyl) Capsules for the Treatment of Very High Triglycerides (VHTG)
January 24, 2013 07:30 ET
|
Amarin Corporation plc
-First and Only FDA Approved Pure-EPA Omega-3 Prescription Therapy Now Available-
-Vascepa Reduces VHTG Without Raising LDL Cholesterol-
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 24, 2013...
Amarin Announces First Notification of U.S. Patent Allowance Based on ANCHOR Clinical Trial Results
January 23, 2013 11:28 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 23, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Publication of Additional Inflammatory Marker Data From MARINE and ANCHOR Phase 3 Clinical Trials in the American Journal of Cardiovascular Drugs
January 22, 2013 07:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Notification of Patent Allowance for U.S. Application 13/610,217 Related to Vascepa(R) and FDA Approved MARINE Indication
January 11, 2013 07:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 11, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin to Present at the 31st Annual J.P. Morgan Healthcare Conference
January 02, 2013 17:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Submission of a Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
January 02, 2013 07:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Submission of Supplemental New Drug Application for Chemport, Inc. as an Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
December 19, 2012 07:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 19, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...